Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4612625 | 1.00 | LMNA (0.41) | LMNATSHRTHRBLPAR2LPAR3 | |
| SCHEMBL4612788 | 1.00 | LMNA (0.41) | LMNATSHRTHRBLPAR2LPAR3 | |
| SCHEMBL4612489 | 1.00 | LMNA (0.41) | LMNATSHRTHRBLPAR2LPAR3 | |
| SCHEMBL4616017 | 1.00 | LMNA (0.41) | LMNATSHRTHRBLPAR2LPAR3 | |
| SCHEMBL946330 | 1.00 | LMNA (0.41) | LMNATSHRTHRBLPAR2LPAR3 | |
| SCHEMBL945866 | 1.00 | LMNA (0.41) | LMNATSHRTHRBLPAR2LPAR3 | |
| SCHEMBL4613469 | 1.00 | LMNA (0.41) | LMNATSHRTHRBLPAR2LPAR3 | |
| SCHEMBL4612616 | 1.00 | LMNA (0.41) | LMNATSHRTHRBLPAR2LPAR3 | |
| SCHEMBL6152804 | 0.98 | LMNA (0.39) | LMNATSHRTHRBLPAR2LPAR3 | |
| SCHEMBL6152487 | 0.98 | LMNA (0.39) | LMNATSHRTHRBLPAR2LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12508217-B2 | Cosmetic compositions comprising high amounts of hydroxypropyl tetrahydropyrantriol | L'OREAL (FR) | 2025-12-30 | — | — | US | claimed |
| US-12435242-B2 | Compositions, devices, and methods for improving a surface property of a substrate | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2025-10-07 | — | — | US | claimed |
| US-20250163297-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR IMPROVING A SURFACE PROPERTY OF A SUBSTRATE | AICP III LP | 2025-05-22 | — | — | US | claimed |
| US-12306373-B2 | Low melting point ionic liquids for infra-red liquid lens design | CORNING INCORPORATED (US) | 2025-05-20 | — | — | US | claimed |
| EP-4422579-A1 | COSMETIC COMPOSITIONS COMPRISING HIGH AMOUNTS OF HYDROXYPROPYL TETRAHYDROPYRANTRIOL | L'OREAL (FR) | 2024-09-04 | — | — | EP | claimed |
| WO-2024107350-A1 | CONDUCTIVE LIQUID FORMULATIONS FOR ELECTROWETTING OPTICAL DEVICES | CORNING INCORPORATED (US) | 2024-05-23 | — | — | WO | claimed |
| US-20240168280-A1 | CONDUCTIVE LIQUID FORMULATIONS FOR ELECTROWETTING OPTICAL DEVICES | CORNING INCORPORATED | 2024-05-23 | — | — | US | claimed |
| EP-3419591-B1 | PROCESS FOR PREPARING A SILICONE ELASTOMER AND PERSONAL CARE COMPOSITION CONTAINING THE ELASTOMER | UNILEVER IP HOLDINGS B V (NL) | 2023-08-16 | — | — | EP | claimed |
| US-20230137659-A1 | COSMETIC COMPOSITIONS COMPRISING HIGH AMOUNTS OF HYDROXYPROPYL TETRAHYDROPYRANTRIOL | L'OREAL (FR) | 2023-05-04 | — | — | US | claimed |
| WO-2023076458-A1 | COSMETIC COMPOSITIONS COMPRISING HIGH AMOUNTS OF HYDROXYPROPYL TETRAHYDROPYRANTRIOL | L'OREAL (FR) | 2023-05-04 | — | — | WO | claimed |
| EP-1112053-A4 | ORGANOSILICONE COMPOSITIONS FOR PERSONAL CARE | CLARIANT LSM ITALIA SPA (US) | 2002-01-02 | — | — | EP | claimed |
| EP-1124530-A1 | MIXTURES OF TRIMETHYLSILYLATED SILICAS AND ALKYLSILOXANES | Clariant Life Science Molecules (Florida) Inc. (US) | 2001-08-22 | — | — | EP | claimed |
| US-6258365-B1 | SILICONE-HYDROCARBON HYBRID FLUID COMPROSING TRISILOXANE OR TRIS(SILOXY)SILANE COMPOUND; COSMETICS FOR DRY SKIN TREATMENT | ARCHIMICA (FLORIDA), INC. | 2001-07-10 | — | — | US | claimed |
| EP-1112053-A1 | ORGANOSILICONE COMPOSITIONS FOR PERSONAL CARE | Clariant Life Science Molecules (Florida) Inc. (US) | 2001-07-04 | — | — | EP | claimed |
| EP-1006988-A1 | HIGH PURITY BRANCHED ALKYLSILSESQUIOXANE FLUIDS | ARCHIMICA (FLORIDA), Inc. (US) | 2000-06-14 | — | — | EP | claimed |
| WO-2000024364-A1 | MIXTURES OF TRIMETHYLSILYLATED SILICAS AND ALKYLSILOXANES | CLARIANT LIFE SCIENCE MOLECULES (FLORIDA) INC. (US) | 2000-05-04 | — | — | WO | claimed |
| WO-2000013653-A1 | ORGANOSILICONE COMPOSITIONS FOR PERSONAL CARE | CLARIANT LIFE SCIENCE MOLECULES (FLORIDA) INC. (US) | 2000-03-16 | — | — | WO | claimed |
| US-6036967-A | Mixtures of trimethylsilylated silicas and alkylsiloxanes | ARCHIMICA (FLORIDA), INC. (US) | 2000-03-14 | — | — | US | claimed |
| US-5932231-A | High purity branched alkylsilsesquioxane fluids | PCR, INC. (US) | 1999-08-03 | — | — | US | claimed |
| WO-1999002123-A1 | HIGH PURITY BRANCHED ALKYLSILSESQUIOXANE FLUIDS | ARCHIMICA (FLORIDA) INC. (US) | 1999-01-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137659-A1 | COSMETIC COMPOSITIONS COMPRISING HIGH AMOUNTS OF HYDROXYPROPYL TETRAHYDROPYRANTRIOL | DHCR24, CYP24A1, CYP2R1 | LMNA 3303/4885TSHR 3754/4885THRB 3437/4885 |
| US-12508217-B2 | Cosmetic compositions comprising high amounts of hydroxypropyl tetrahydropyrantriol | CYP24A1, CYP2R1, CCND3 | LMNA 1128/4885TSHR 2851/4885THRB 1796/4885 |
| US-12306373-B2 | Low melting point ionic liquids for infra-red liquid lens design | IK, CRYZ, CRYAA | LMNA 124/4885TSHR 2645/4885THRB 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.